Pramlintide

Dosing from the Literature

Published for fat loss: obesity trials exist (Aronne et al., 2007; Smith et al., 2008), but the approved doses (15–120 µg before meals) are for diabetes (Symlin label). Not published: an approved weight-loss dose.

The FDA label sets the doses, which differ for type 1 and type 2 diabetes: an injection under the skin immediately before each major meal, meaning one of at least 250 kcal or 30 g of carbohydrate (Symlin label).

What It Is

Pramlintide (brand name Symlin, now an AstraZeneca product) is a synthetic analog of human amylin, a 37-amino-acid peptide hormone made by the pancreas's beta cells (Symlin label; Hay et al., 2015). Amylin is stored with insulin in the same secretory granules and released with it in response to food (Symlin label). It exerts complementary metabolic effects that insulin cannot achieve alone: suppression of inappropriate postprandial glucagon, delay of gastric emptying, and central satiety signaling. In type 1 diabetes, endogenous amylin production is lost with β-cell destruction (alongside insulin deficiency), which is the mechanistic rationale for pramlintide's use as an adjunct to insulin in T1D.

The development of pramlintide required solving a fundamental engineering problem inherent to native human amylin: the wild-type hormone is intrinsically amyloidogenic and aggregates readily into β-sheet amyloid fibrils at therapeutic concentrations. In fact, amyloid deposition from human amylin is part of the pathophysiology of type 2 diabetes (islet amyloid is found in ~90% of T2D pancreatic autopsies). For a therapeutic, this aggregation propensity is disqualifying. Pramlintide solves this by substituting three residues (Pro25, Pro28, Pro29) with proline — proline's ring structure disrupts β-sheet formation, eliminating the amyloidogenic tendency while preserving amylin receptor agonism. The result is a synthetic 37-amino-acid peptide with the pharmacological activity of native amylin but without the aggregation liability.

Pramlintide received FDA approval in March 2005 for use as adjunctive therapy with mealtime insulin in adults with type 1 diabetes or type 2 diabetes who have failed to achieve glycemic targets despite optimal insulin therapy. The approval indication requires concurrent insulin use — pramlintide is not a monotherapy and is not approved for weight loss as a primary indication. The label carries a boxed warning: used with insulin, pramlintide increases the risk of severe hypoglycemia, particularly in type 1 diabetes, and the label cuts mealtime insulin doses by 50% when pramlintide is started (Symlin label).

In contemporary diabetes and obesity therapeutics, pramlintide is the foundational compound of a broader amylin-agonist therapeutic class. Its successors include cagrilintide (Novo Nordisk), a C-18 fatty acid-conjugated long-acting amylin analog supporting once-weekly dosing, being developed as CagriSema in combination with semaglutide; and eloralintide (Eli Lilly, and related), a next-generation amylin analog also engineered for weekly dosing. Unlike pramlintide, which is injected before each major meal (Symlin label), cagrilintide was given once a week in its trials (Lau et al., 2021).

Mechanism of Action

Pramlintide acts as an analog of amylin, a hormone that pancreatic beta cells release with insulin after food. In human studies it slows gastric emptying, reduces the rise in glucagon after meals and modulates satiety, lowering calorie intake (Symlin label).

• Amylin receptor agonism — receptor / RAMP complexes — Pramlintide is an analog of human amylin (Symlin label). Amylin's receptors are G protein-coupled receptors built from a core receptor protein paired with receptor activity-modifying proteins (RAMPs), which gives several receptor subtypes, and amylin acts on several organ systems (Hay et al., 2015). Amylin, calcitonin and CGRP appear to act on a family of related receptors, which seem to be coupled to adenylyl cyclase in many cases; amylin's effects on skeletal muscle run largely through the cAMP pathway (Pittner et al., 1994).
• Postprandial glucagon suppression — In human studies, pramlintide reduces the rise in glucagon after meals; in nonclinical studies, amylin suppresses glucagon secretion that insulin alone does not normalize (Symlin label). People with type 1 or type 2 diabetes secrete less of both insulin and amylin after food (Symlin label; Kruger et al., 1999).
• Gastric emptying delay — In human studies, pramlintide slows gastric emptying; in nonclinical studies, amylin slowed the release of food from the stomach to the small intestine without changing overall nutrient absorption, one of the ways it slows the appearance of glucose after meals (Symlin label).
• Central satiety signaling — circumventricular organs — Amylin acts mainly in the brain's circumventricular organs and interacts with other metabolically active hormones such as cholecystokinin, leptin and estradiol (Hay et al., 2015). In human studies, pramlintide lowers calorie intake (Symlin label); in the year-long diabetes trials, weight ended 1.2–2.1 kg lower than on placebo (Ratner et al., 2004; Hollander et al., 2003).
• Used with insulin, not instead of it — Pramlintide alone does not cause hypoglycemia, and the label approves it only as an add-on to mealtime insulin (Symlin label).
• Liver glucose output, through glucagon — In nonclinical studies, amylin's suppression of glucagon led to suppression of glucose output from the liver. The label's account of pramlintide's effect after meals is slower gastric emptying, a smaller glucagon rise and lower food intake (Symlin label).
• Short plasma half-life (~48 min) — About 48 minutes in healthy people, with peak levels about 20 minutes after an injection; the label gives a dose before each major meal (Symlin label).
• Calcitonin-like activity — Native amylin is related to calcitonin and CGRP, with relatively potent calcitonin-like activity on bone metabolism and weaker CGRP-like activity on blood vessels (Pittner et al., 1994).
• The amylin-agonist class — Pramlintide is the amylin-based peptide in clinical use for type 1 and type 2 diabetes, and obesity studies suggest amylin agonists could also help with weight loss, especially combined with other agents (Hay et al., 2015). Cagrilintide, a long-acting amylin analog, has a half-life of 159–195 hours and was given once a week in trials (Enebo et al., 2021; Lau et al., 2021).

What the Research Shows

FDA approved pramlintide in March 2005 on randomized, double-blind, placebo-controlled trials in type 1 and type 2 diabetes lasting 26 to 52 weeks (Symlin label; Drugs@FDA).

• Type 1 diabetes pivotal trials (Whitehouse et al., Diabetes Care 2002; PMID 11919132; Ratner et al., Diabet Med 2004; PMID 15498087) — 52-week, placebo-controlled RCTs in adults with type 1 diabetes (480 and 651 patients). Pramlintide added to mealtime insulin lowered HbA1c more than placebo: 0.67% vs 0.16% at week 13 (Whitehouse), 0.29–0.34% vs 0.04% at week 52 (Ratner). Weight fell slightly instead of rising: −0.4 kg vs +0.8 kg on placebo at week 52 (Ratner).
• Type 2 diabetes pivotal trials (Hollander et al., Diabetes Care 2003; PMID 12610038; Ratner et al., Diabetes Technol Ther 2002; PMID 12017421) — 52-week, placebo-controlled RCTs in insulin-treated people with type 2 diabetes (656 and 538 patients). HbA1c fell 0.62% from baseline by week 52 on 120 µg twice daily (Hollander) and 0.6% on 150 µg three times daily (Ratner), more than on placebo. Weight fell 1.4 kg vs a 0.7 kg gain on placebo (Hollander), and the HbA1c drop came without more insulin use (Ratner).
• Postprandial glucose excursion reduction — Multiple studies using continuous glucose monitoring (CGM) demonstrate significant reduction in postprandial glucose excursions with pramlintide, improving glycemic variability beyond what HbA1c captures.
• Satiety and meal-size reduction — A single dose given an hour before an unlimited buffet cut total calorie intake by about 21% (30 µg, in type 1 diabetes) and 23% (120 µg, in type 2 diabetes) vs placebo, without shortening the meal (Symlin label).
• Weight loss sustained over 1 year — Long-term extension studies support sustained ~2–3 kg mean weight loss at 12–24 months of pramlintide use.
• Combination with metformin — Pramlintide is compatible with concurrent metformin; the combined glycemic effect is additive.
• Combination with basal insulin — Efficacy is established when pramlintide is added to patients on basal-bolus insulin regimens.
• Meta-analyses — Systematic reviews confirm modest but consistent glycemic and weight effects with the 3x-daily dosing pattern.
• CagriSema Phase 3 validation (pharmacology class precedent) — The cagrilintide + semaglutide ("CagriSema") combination pipeline has produced weight loss of ~22–23% at 68 weeks — substantially greater than either component alone. This retrospectively validates the amylin-agonist class concept pioneered by pramlintide.
• Cagrilintide phase 1b (Enebo et al., Lancet 2021) — A multiple-ascending-dose trial of cagrilintide with semaglutide 2.4 mg in 96 people, which extended the class to weekly long-acting amylin analogues.

Human Data

Pramlintide has one of the more mature human evidence bases of any peptide on this site — over 20 years of Phase III and post-marketing data:

• T1D Phase III (Whitehouse 2002; Ratner 2004) — Multiple pivotal trials establishing efficacy in adults with type 1 diabetes on intensive insulin therapy.
• T2D Phase III (Hollander 2003; Ratner 2004) — Pivotal trials in insulin-treated type 2 diabetes.
• FDA approval 2005 — Symlin (pramlintide acetate) approved by the FDA in March 2005 for use as an adjunct to mealtime insulin in T1D and insulin-treated T2D.
• Weight loss trials in obesity (Aronne et al., 2007; Smith et al., 2008) — In 204 adults with obesity, with or without type 2 diabetes and none on insulin, pramlintide up to 240 µg three times a day before meals cut weight 3.6 kg more than placebo in those who completed 16 weeks (Aronne et al., 2007). In 411 adults with obesity and no diabetes, on a lifestyle program, 120 µg three times a day or 360 µg twice a day cut it 6.1–7.2 kg more than placebo at 12 months, among the 146 still evaluable (Smith et al., 2008).
• Pramlintide + metreleptin combination — Proof-of-concept trials in the late-2000s explored combination of pramlintide with metreleptin (synthetic leptin) for obesity; program discontinued.
• Continuous glucose monitoring studies — Multiple studies document pramlintide's improvement in glycemic variability beyond HbA1c.
• Closed-loop insulin delivery context — Research in automated insulin delivery ("artificial pancreas") systems has explored pramlintide as adjunct to improve postprandial control; protocols developed but not standard practice.
• FDA prescribing information (Symlin label, current) — Labeled dosing and safety guidance; boxed warning about severe hypoglycemia when combined with insulin.
• Post-marketing safety surveillance — Since approval, injection site reactions and pancreatitis have been reported; the label notes that voluntary reports cannot reliably give their frequency or establish that the drug caused them (Symlin label).
• Amylin receptor class validation — Pramlintide's Phase III data and clinical use established the amylin-agonist target class that now supports cagrilintide (weekly Novo Nordisk) and eloralintide (weekly Eli Lilly next-generation) development programs.

Pramlintide is a mature, FDA-approved drug with rigorous Phase III data and decades of post-marketing experience. This is a fundamentally different evidence base from most "research peptides" on this site.

Reconstitution & Storage

The current label lists Symlin only as a ready-to-use solution in two disposable multidose pens, SymlinPen 60 and SymlinPen 120, so there is nothing to reconstitute (Symlin label). The earlier 600 µg/mL vial is listed as discontinued (Drugs@FDA).

• Strength — 1,000 µg/mL (1 mg/mL) in both pens (Symlin label); the discontinued vial held 600 µg/mL (Drugs@FDA).
• SymlinPen 60 — A 1.5 mL disposable multidose pen for doses of 15, 30, 45 or 60 µg, the label's type 1 diabetes doses (Symlin label).
• SymlinPen 120 — A 2.7 mL disposable multidose pen for doses of 60 or 120 µg, the label's type 2 diabetes doses (Symlin label).
• Storage (unopened) — The label lists the refrigerator at 2–8°C (36–46°F), never frozen, and not using a pen that has been frozen (Symlin label).
• Storage (in use) — After first use, the label lists the refrigerator or up to 30°C (86°F) for 30 days, and discarding the pen after 30 days whether or not it was refrigerated (Symlin label).
• Protected from light — The label lists keeping pens that are not in use out of the light (Symlin label).
• Injection sites — The label lists the abdomen or thigh, under the skin; not the arm, where absorption varies; rotating sites; a site more than 2 inches from any insulin injection; and letting the pen reach room temperature first, to reduce injection-site reactions (Symlin label).
• Labeling advises against mixing with insulin — The label calls for separate injections, never mixed: premixed in one syringe, pramlintide's peak level fell by up to 40% and its total exposure rose by up to 36%, insulin levels rose too, and the label warns this may lead to poor glucose control or hypoglycemia (Symlin label).
• Inspection — The solution is clear and colorless; the label says not to use it if it looks cloudy or colored or has lumps or particles (Symlin label).

→ Calculator — vial-to-syringe math

Side Effects & Risks

The side effects below are from the label's placebo-controlled trials; since approval, injection site reactions and pancreatitis have also been reported (Symlin label).

• Severe hypoglycemia (boxed warning) — The label's boxed warning: used with insulin, pramlintide increases the risk of severe hypoglycemia, particularly in type 1 diabetes, and when it occurs it is seen within 3 hours of an injection. Pramlintide alone does not cause hypoglycemia. In the label's trials that made no insulin cut at the start, severe hypoglycemia needing another person's help or medical treatment occurred in the first 3 months in 16.8% on pramlintide vs 10.8% on placebo in type 1 diabetes, and 8.2% vs 2.1% in type 2. The label's precautions are careful patient selection and instruction, a 50% cut in mealtime insulin at the start, and frequent glucose checks before and after meals (Symlin label).
• Nausea (most common side effect) — 48% on pramlintide vs 17% on placebo in the label's type 1 diabetes trials, and 28% vs 12% in type 2. It is more frequent early in treatment and declines with time in most people; the label says gradual dose increases minimize it, and lowers the dose if significant nausea persists (Symlin label).
• Vomiting — 11% vs 7% on placebo in type 1 diabetes, and 8% vs 4% in type 2 (Symlin label).
• Anorexia (loss of appetite) — 17% vs 2% on placebo in type 1 diabetes, and 9% vs 2% in type 2 (Symlin label).
• Abdominal pain — 8% vs 7% on placebo in type 2 diabetes (Symlin label).
• Headache — 13% vs 7% on placebo in type 2 diabetes (Symlin label).
• Fatigue / dizziness — Fatigue 7% vs 4% on placebo in both type 1 and type 2 diabetes; dizziness 5–6% vs 4%. Dizziness is also on the Medication Guide's list of low-blood-sugar symptoms (Symlin label).
• Injection site reactions — Redness, swelling or itching at the site; these minor reactions usually resolve in a few days to a few weeks, and have also been reported since approval (Symlin label).
• Drug interactions — delayed gastric emptying — Pramlintide slows gastric emptying, which may delay the absorption of oral medicines taken with it. For oral drugs whose quick onset or threshold level matters, such as pain relievers, antibiotics and oral contraceptives, the label times them at least 1 hour before or 2 hours after the injection. It does not recommend pramlintide for people taking other drugs that alter gut motility (Symlin label).
• Contraindications — Serious hypersensitivity to pramlintide or any product component, hypoglycemia unawareness, and confirmed gastroparesis. The label also rules out people with an HbA1c above 9%, recurrent severe hypoglycemia needing help in the past 6 months, poor adherence to their insulin regimen or glucose self-monitoring, a need for drugs that speed gut motility, and children (Symlin label).
• Pregnancy — The current label carries no letter category: reports in pregnancy are too few to judge the risk. In rats, birth defects (neural tube defects, cleft palate, exencephaly) occurred at 10 and 47 times the human exposure, but not in rabbits at up to 9 times; human, rabbit and rat placentas showed little transfer of the drug (Symlin label).
• Pediatric use — Safety and effectiveness are not established in children, and the label does not recommend pramlintide for them because of the risk of severe hypoglycemia (Symlin label).
• WADA status — Not specifically named on the Prohibited List as of 2026. Metabolic use case without direct performance-enhancement relevance.

Bloodwork & Monitoring

The FDA label sets no routine schedule of laboratory tests for pramlintide. Before it is started, the label reviews HbA1c, recent blood glucose records, any history of insulin-induced hypoglycemia, the insulin regimen and body weight. While it is started or raised, the label calls for frequent blood glucose checks before and after meals and at bedtime, and treats more frequent mild-to-moderate hypoglycemia as a warning sign of severe hypoglycemia (Symlin label). The year-long trials tracked HbA1c, body weight, insulin use and severe hypoglycemia (Ratner et al., 2002; Hollander et al., 2003).

Practical User Notes

• Not a monotherapy — The label approves pramlintide only as an add-on for people who already use mealtime insulin and have not reached glucose control despite optimal insulin (Symlin label).
• Mealtime insulin reduced 50% on initiation — The label cuts mealtime insulin by 50% when pramlintide starts; it names no cut to basal insulin. In its type 1 diabetes trials that made no such cut, severe hypoglycemia needing another person's help or medical treatment occurred in 16.8% on pramlintide vs 10.8% on placebo in the first 3 months (Symlin label).
• Slow titration — The label starts at 15 µg (type 1) or 60 µg (type 2) and raises the dose only after at least 3 days without clinically significant nausea; it says gradual titration minimizes how often and how badly nausea occurs (Symlin label).
• Nausea — The most common side effect in the label's trials, most frequent early in treatment; the label lowers the dose if significant nausea persists (Symlin label).
• Injection timing — The label times each dose immediately before a major meal of at least 250 kcal or 30 g of carbohydrate (Symlin label).
• Injections kept separate from insulin — The label calls for separate injections, never mixed, at a site more than 2 inches from the insulin injection; mixing changed blood levels of both drugs (Symlin label).
• Glucose checks while starting — The label calls for frequent checks before and after meals and at bedtime when pramlintide is started or raised; in its trials, severe hypoglycemia was more common in the first 3 months than in months 4 to 6 (Symlin label).
• Hypoglycemia recognition and treatment — The Medication Guide lists warning symptoms such as shakiness, sweating, confusion, dizziness and a fast heartbeat, and says to carry fast-acting sugar, such as glucose tablets or juice, or injectable glucagon at all times (Symlin label).
• Weight — Weight loss is not an approved use: the label's indication is blood sugar control (Symlin label). In the year-long trials, weight fell 1.4 kg on pramlintide vs a 0.7 kg gain on placebo in type 2 diabetes (Hollander et al., 2003), and 0.4 kg vs a 0.8 kg gain in type 1 (Ratner et al., 2004).
• SymlinPen injectors are not shared — The label says a pen must never be shared, even with a new needle, because of the risk of passing on blood-borne infections; it also calls for a new needle for each injection (Symlin label).

Commonly Stacked With

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching pramlintide often also look at these:

Next Steps

References

1. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784-790. PMID: 12610038.
2. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25(4):724-730. PMID: 11919132. (Core T1D Phase III.)
3. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204-1212. PMID: 15498087.
4. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002;4(1):51-61. PMID: 12017421.
5. Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92(8):2977-2983. PMID: 17504894. (Weight loss trial in non-diabetic obesity.)
6. Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31(9):1816-1823. PMID: 18753666.
7. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ. 1999;25(3):389-397. PMID: 10531859. (Foundational clinical amylin physiology review.)
8. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67(3):564-600. PMID: 26071095. (Comprehensive amylin pharmacology review.)
9. Pittner RA, Albrandt K, Beaumont K, Gaeta LS, Koda JE, Moore CX, Rittenhouse J, Rink TJ. Molecular physiology of amylin. J Cell Biochem. 1994;55 Suppl:19-28. PMID: 7929615. (Foundational molecular pharmacology of amylin.)
10. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. PMID: 33894838. (CagriSema Phase 1b validating pramlintide-class extension.)
11. Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID: 34798060.
12. Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30(11):2794-2799. PMID: 17698615.
13. US Food and Drug Administration. Symlin (pramlintide acetate) injection prescribing information. AstraZeneca Pharmaceuticals. Current version accessed April 2026.
14. Cooper GJ. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev. 1994;15(2):163-201. PMID: 8026387. (Foundational amylin structural biology.)
15. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)

Related Research

• CagrilintideLong-Acting Amylin Analog
• CagriSemaAmylin Analog + GLP-1 Agonist
• EloralintideSelective Amylin Receptor Agonist
• 5-Amino-1MQNNMT Inhibitor
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.
• PetrelintideOnce-Weekly Amylin Analog (investigational)